Yizun Biomedicine’s CNK-UT Cell Therapy Initiates Patient Enrollment for Solid Tumor Trial
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...
Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...
Zelgen Biopharmaceuticals’ ZG0895 Receives FDA Approval for Clinical Trials in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared...
Philips Agrees to $62 Million Settlement with SEC Over China Marketing Practices
The US Securities and Exchange Commission (SEC) has announced that Dutch device company Philips (BVMF:...
Drug Farm Secures $27 Million in Series C Financing to Advance HBV Treatments
Drug Farm, a Sino-US biotech company specializing in hepatitis B virus (HBV) treatments, oncology, and...
Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong
Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful...
BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors
US-based biotech company BiOneCure Therapeutics Inc. has entered into a strategic collaboration with China-based Nanjing...
Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study
China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of...
Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD
Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing...
Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy
Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an...
Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D
Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership...
CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces
The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates...
COVID-19 Disruptions Lead to Soaring Lab Monkey Prices, Impacting US Drug Development
The COVID-19 pandemic has led to a significant reduction in the export of laboratory monkeys...
Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...
Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis
China-based Rona Therapeutics Inc. and Keymed Biosciences (HKG: 2162) have unveiled a strategic collaboration aimed...
Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management
At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare...
LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing...
ExoRNA Bio Secures Tens of Millions in Financing to Advance Huntington’s Disease Pipeline
ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of...
Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development
Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186),...